| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S80351-1mg促销 |
99.20% | ￥176.00 ￥175.00 |
5 | - | - | - | - |
|
S80351-5mg促销 |
99.20% | ￥665.00 ￥580.00 |
7 | - | - | - | - |
|
S80351-10mg买3赠1 |
99.20% | ￥1010.00 |
6 | - | - | - | - |
|
S80351-25mg买3赠1 |
99.20% | ￥2020.00 |
8 | - | - | - | - |
|
S80351-50mg买3赠1 |
99.20% | ￥3810.00 |
4 | - | - | - | - |
|
| 产品描述： | LDN-212854 is a bone morphogenetic protein (BMP) inhibitor that potently inhibits ALK2 (IC50: 1.3 nM). LDN-212854 also inhibits ALK1 (IC50: 2.40 nM). LDN-212854 can be used in the research of fibrodysplasia ossificans progressive and cancers, such as hepatocellular carcinoma (HCC) |
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | ACVR1：1.3 nM (IC50)；ALK1：2.4 nM (IC50)；BMPR1A：85.8 nM (IC50)；ALK4：2133 nM (IC50)；ALK5：9276 nM (IC50);ALK;TGF-beta/Smad | ||||||||||||||||||||
| 体内研究： | LDN-212854 (intraperitoneal injection, 6 mg/kg, twice daily for 4 weeks) potently inhibits heterotopic ossification in an inducible transgenic mutant ALK2 mouse model of fibrodysplasia ossificans progressiva. LDN-212854 (intraperitoneal injection, 6 mg/kg, twice daily for 10-14 days) suppresses HCC tumor progression through repression of ID1 in HCC xenografts model | ||||||||||||||||||||
| 参考文献： | 1. Mohedas AH, et al. Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chem Biol. 2013;8(6):1291-302. 2. Han Chen, et al. BMP9-ID1 signaling promotes EpCAM-positive cancer stem cell properties in hepatocellular carcinoma. Mol Oncol. 2021 Aug;15(8):2203-2218. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京